Amylyx Pharmaceuticals: Back From The Dead [Seeking Alpha]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Seeking Alpha
Avexitide targets post-bariatric hypoglycemia, an underserved market with no approved therapies and significant unmet need. Street sentiment is bullish on AMLX, but current valuation appears fair given projected sales and patient penetration. An analysis around Amylyx Pharmaceuticals follows in the paragraphs below. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » jxfzsy/iStock via Getty Images Shares of endocrine and neurodegenerative therapy concern Amylyx Pharmaceuticals, Inc. ( AMLX have surged by more than 750% off their 2024 nadir after its ALS product flunked a confirmatory Phase 3 trial. The rally was prompted by the More on my IG service Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial i
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Amylyx Pharmaceuticals Co-Chief Executive Sells AMLX 138K Shares for $1.9 Million [Yahoo! Finance]Yahoo! Finance
- HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases [Yahoo! Finance]Yahoo! Finance
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- 2/4/26 - Form 4
- AMLX's page on the SEC website